A randomised phase II and pharmacokinetic study of oral ZD1839 given continuously with oxaliplatin or cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Study identifier:1839IL/0058
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised phase II and pharmacokinetic study of oral ZD1839 given continuously with oxaliplatin or cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Medical condition
head and neck cancer
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Feb 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
